Wells Fargo analyst Chris Carey lowered the firm’s price target on Procter & Gamble to $158 from $177 and keeps an Overweight rating on the shares. The firm is broadly lowering estimates for the sector ahead of quarterly results. The earnings revisions were anchored by unique, company-specific commodity sheets in all Wells’ models, the firm adds. This makes the margin builds much more specific to the track of this inflationary backdrop, namely into Q4 2026 and 2027, with embedded recovery into 2028.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PG:
- Procter & Gamble price target lowered to $166 from $170 at UBS
- 3 Vanguard ETFs Are Beating the S&P 500 in 2026 – Should You Buy?
- 3 Best Dividend Aristocrat Stocks to Buy Now, 04/02/2026
- Procter & Gamble price target lowered to $142 from $156 at TD Cowen
- Procter & Gamble price target lowered to $162 from $171 at Deutsche Bank